Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | OXER1 | Q8TDS5 | 6/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416196 | 1.00 | MMP12 (0.44) | MMP12MMP13BCAT1IDO1CYP1A2 | |
| SCHEMBL6412799 | 0.93 | MMP12 (0.45) | MMP12MMP13BCAT1IDO1CYP1A2 | |
| SCHEMBL6412804 | 0.93 | MMP12 (0.45) | MMP12MMP13BCAT1IDO1CYP1A2 | |
| SCHEMBL6417757 | 0.91 | MMP12 (0.44) | MMP12MMP13BCAT1CYP1A2CYP2D6 | |
| SCHEMBL6420264 | 0.91 | MMP12 (0.44) | MMP12MMP13BCAT1CYP1A2CYP2D6 | |
| SCHEMBL6420266 | 0.91 | MMP12 (0.44) | MMP12MMP13BCAT1CYP1A2CYP2D6 | |
| SCHEMBL6417761 | 0.91 | MMP12 (0.44) | MMP12MMP13BCAT1CYP1A2CYP2D6 | |
| SCHEMBL6416490 | 0.88 | MMP12 (0.42) | MMP12MMP13CYP2C19LMNA | |
| SCHEMBL6416486 | 0.88 | MMP12 (0.42) | MMP12MMP13CYP2C19LMNA | |
| SCHEMBL6420195 | 0.87 | MMP12 (0.49) | MMP12MMP13BCAT1IDO1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828726-B1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | claimed |
| EP-0828726-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| US-5665764-A | FOR TREATING DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT COMPANY (US) | 1997-09-09 | — | — | US | claimed |
| WO-1996038434-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| EP-0828726-B1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0828726-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5665764-A | FOR TREATING DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1996038434-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885BCAT1 1525/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885BCAT1 1525/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885BCAT1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.